AZBio team member Dylan N. Peay earned his PhD in Behavioral Neuroscience from Arizona State University. Dr. Peay serves as Manager, Entrepreneurial Programs and Grants on the AZBio team.
Author Archive: AZBio
Study Links Inherited Mutations to Okur-Chung Neurodevelopment Syndrome
PHOENIX, AZ – August 16, 2023 — Okur-Chung neurodevelopmental syndrome (OCNDS) has long perplexed the medical community with its varied manifestations and genetic origins. A recent study, led by researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, has revealed insights into the hereditary aspects of OCNDS, shedding light on the genetic underpinnings and potential implications for affected families. Continue reading
GT Medical Technologies Awarded the Arizona Bioscience Company of the Year for Disrupting the Status Quo in Brain Tumor Treatment
TEMPE, Ariz., Aug. 15, 2023 /PRNewswire/ — The Arizona Bioindustry Association, Inc. (AZBio) announced that GT Medical Technologies, Inc. (GT MedTech) will be honored as the Arizona Bioscience Company of the Year at the 2023 AZBio Awards and 20th Anniversary Celebration on Sept. 27 in Phoenix, Arizona.Continue reading
Applications Open for 2023 Flinn Seed Grants
The Flinn Foundation Seed Grants to Promote Translational Research Program opened the application for its next cycle of funding on Monday, Aug. 14, 2023. The deadline to apply is Monday, Oct. 2, 2023.Continue reading
Dr. David Alberts: A legacy of encouragement, innovation and scientific rigor
Dr. Alberts, who passed away on July 29 at the age of 83, not only assisted in creating the Arizona Cancer Center in 1976, but he also developed the center’s Cancer Prevention and Control Program into one of the top programs in the United States. He was honored with the inaugural AZBio Pioneer Award in 2012.
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow™ Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device
Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with HydrocephalusContinue reading
Unify Medical Announces know-how agreement with Mayo Clinic for Fluorescence-Guided Visualization
Unify Medical, Inc., a privately-held, smart, surgical visualization technology company, announced that, through a know-how agreement with Mayo Clinic to assess and develop clinical applications using Unify’s fluorescence-guided visualization technology.Continue reading
Langham Upgrades Phoenix GMP Warehouse, CRT Expansion
Langham Logistics, an Indiana-based warehousing and transportation company with a focus in life sciences, today announced an adaptation of the second half of its Arizona building to GMP controlled room space. More than 9,000 newly-converted controlled room temperature (CRT) pallet positions opened for full operations on June 1st to serve the West Coast’s cold chain warehousing and distribution demands.Continue reading
Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms
Pivotal trial to be conducted at multiple sites, primarily in the U.S., using novel single-use, endovascular system comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucoseContinue reading
Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
- Aqualung Therapeutics will initiate moderate/severe ARDS patient recruitment for U.S. and Australia hospital sites in August 2023.
- Aqualung appoints Jackson Streeter MD to their board of directors bringing expertise to Aqualung to support advancing of ALT-100 mAb as a novel therapeutic for inflammatory and fibrotic diseases (ARDS, radiation-induced lung fibrosis, pulmonary arterial hypertension)